Roche will acquire GeneWEAVE BioSciences, a US diagnostics company whose lead investor is China’s Decheng Capital, for $425 million; WuXi PharmaTech, China’s largest CRO/CMO, formally accepted the $3.3 billion merger offer that will take the company private; Ascentage Pharma of Shanghai closed a $15.5 million Round A financing to develop its oncology portfolio; FortuneRock (China), a Beijing clinical-stage biotech, has been approved to IPO and list its shares on China’s Third Board; Hua Medicine of Shanghai reported that its GKA treatment for Type 2 diabetes was very effective in a Phase Ic trial; Singapore’s ASLAN Pharma received US Orphan Drug Designation for a bile duct cancer treatment; and WuXi PharmaTech and TruTag Technologies of Hawaii completed a test of TruTag’s nanotechnology security technology in solid dose drugs.
Help employers find you! Check out all the jobs and post your resume.
